Up to a $1.7 billion collaboration was terminated when Sanofi canceled an agreement with Lexicon Pharmaceuticals to develop Zynquista™ (sotagliflozin) after type 1 and type 2 diabetes candidate showed mixed results in three Phase III trials, including disappointing outcomes among patients with chronic kidney disease (CKD). Lexicon fired back that Sanofi was breaching the contract, setting up the prospects for a legal battle.

With the French giant’s decision, Lexicon’s shares declined by 66%.

What is Zynquista?

An oral dual inhibitor of sodium-glucose linked transporters 1 and 2 (SGLT-1 and SGLT-2), two proteins responsible for glucose regulation. SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sanofi was interested as Zynquista has demonstrated interesting results in Phase II studies, including reduced hemoglobin A1c (HbA1c) in people with type 1 and type 2 diabetes.

Follow Genentech Engineering and Biotechnology News for more details.

Source: Genetic Engineering & Biotechnology News

Pin It on Pinterest